Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (Mountain Cedar) allergic rhinitis

This multicenter, randomized, double-blind placebo-controlled study was conducted to assess the efficacy and safety of two doses of olopatadine nasal spray as a treatment for SAR (Mountain Cedar season). Patients assessed morning and evening reflective (refl) and instantaneous (inst) nasal and ocula...

Full description

Saved in:
Bibliographic Details
Published in:Journal of allergy and clinical immunology 2004-02, Vol.113 (2), p.S200-S201
Main Authors: Ratner, P.H., Hampel, F.C., Amar, N.J., van Bavel, J.H., Mohar, D., Wall, G.M., Brubaker, M., Drake, M., Potts, S.
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page S201
container_issue 2
container_start_page S200
container_title Journal of allergy and clinical immunology
container_volume 113
creator Ratner, P.H.
Hampel, F.C.
Amar, N.J.
van Bavel, J.H.
Mohar, D.
Wall, G.M.
Brubaker, M.
Drake, M.
Potts, S.
description This multicenter, randomized, double-blind placebo-controlled study was conducted to assess the efficacy and safety of two doses of olopatadine nasal spray as a treatment for SAR (Mountain Cedar season). Patients assessed morning and evening reflective (refl) and instantaneous (inst) nasal and ocular symptoms including rhinorrhea, sneezing, itchy nose and congestion on a 0-3 scale. After a 3-21 day single blind placebo spray run-in period, 677 patients ages 12-81 with a minimum total nasal symptom score (TNSS) of 36 out of a possible 72 were randomized to olopatadine 0.4% (n=229), 0.6% (n=223), or placebo (n=225) 2 sprays/nostril BID for 2 weeks. Olopatadine HCl nasal spray 0.4% & 0.6% were significantly superior to placebo for percent change from baseline in overall refl (p=0.0002 &
doi_str_mv 10.1016/j.jaci.2004.01.164
format article
fullrecord <record><control><sourceid>proquest_elsev</sourceid><recordid>TN_cdi_proquest_journals_1504858468</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674904001654</els_id><sourcerecordid>3239719011</sourcerecordid><originalsourceid>FETCH-LOGICAL-e818-2f4aa9eb559bbdc9670c05353f2d866a3ad2e24dd76b27ddfdb79395544c67833</originalsourceid><addsrcrecordid>eNotkEtLxDAUhYMoOD7-gKuAG120Jm2SJuBGBl-guHEfbpsbTanpmGQE_70dxtXlwDmHcz9CLjirOePqZqxHGELdMCZqxmuuxAFZcWa6SulGHpIVY4ZXqhPmmJzkPLJFt9qsSHqb5g0UcCEifVpPNEKGieZNgl8aMkXvcSjhBylERzN4pH5OtHwiLQmhfGEsdPY0I-Q5Lsmr13kbC4RI1-ggXVOYJkwfYaDpM8RQQj4jRx6mjOf_95S8P9y_r5-ql7fH5_XdS4Wa66rxAsBgL6XpezcY1bGByVa2vnFaKWjBNdgI5zrVN51z3vWdaY2UQgyq0217Si73tZs0f28xFzvO27RMzJZLJrTUQunFdbt34bLkJ2CyeQgYB3QhLY9bNwfLmd1BtqPdQbY7yJZxu0Bu_wBxF3JW</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504858468</pqid></control><display><type>article</type><title>Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (Mountain Cedar) allergic rhinitis</title><source>ScienceDirect Freedom Collection</source><creator>Ratner, P.H. ; Hampel, F.C. ; Amar, N.J. ; van Bavel, J.H. ; Mohar, D. ; Wall, G.M. ; Brubaker, M. ; Drake, M. ; Potts, S.</creator><creatorcontrib>Ratner, P.H. ; Hampel, F.C. ; Amar, N.J. ; van Bavel, J.H. ; Mohar, D. ; Wall, G.M. ; Brubaker, M. ; Drake, M. ; Potts, S.</creatorcontrib><description><![CDATA[This multicenter, randomized, double-blind placebo-controlled study was conducted to assess the efficacy and safety of two doses of olopatadine nasal spray as a treatment for SAR (Mountain Cedar season). Patients assessed morning and evening reflective (refl) and instantaneous (inst) nasal and ocular symptoms including rhinorrhea, sneezing, itchy nose and congestion on a 0-3 scale. After a 3-21 day single blind placebo spray run-in period, 677 patients ages 12-81 with a minimum total nasal symptom score (TNSS) of 36 out of a possible 72 were randomized to olopatadine 0.4% (n=229), 0.6% (n=223), or placebo (n=225) 2 sprays/nostril BID for 2 weeks. Olopatadine HCl nasal spray 0.4% & 0.6% were significantly superior to placebo for percent change from baseline in overall refl (p=0.0002 & <0.0001, respectively) and inst (p=0.0015 & <0.0001, respectively) TNSS over a 2 week period. Olopatadine spray 0.6% was superior to placebo for individual nasal symptoms of runny nose, itchy nose, congestion and sneezing. The 0.4% spray was (generally) less effective than 0.6% but superior to placebo in most cases for the individual nasal symptoms. Treatment with Olopatadine HCl nasal spray 0.4% or 0.6%, BID, was safe and well tolerated. No serious adverse events related to any treatment were reported in this study. Olopatadine HCl nasal spray 0.4% & 0.6% are well tolerated and provide statistically significant improvements in symptoms in patients with seasonal allergic rhinitis.]]></description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2004.01.164</identifier><language>eng</language><publisher>St. Louis: Mosby, Inc</publisher><ispartof>Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.S200-S201</ispartof><rights>2004</rights><rights>Copyright Elsevier Limited Feb 2004</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Ratner, P.H.</creatorcontrib><creatorcontrib>Hampel, F.C.</creatorcontrib><creatorcontrib>Amar, N.J.</creatorcontrib><creatorcontrib>van Bavel, J.H.</creatorcontrib><creatorcontrib>Mohar, D.</creatorcontrib><creatorcontrib>Wall, G.M.</creatorcontrib><creatorcontrib>Brubaker, M.</creatorcontrib><creatorcontrib>Drake, M.</creatorcontrib><creatorcontrib>Potts, S.</creatorcontrib><title>Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (Mountain Cedar) allergic rhinitis</title><title>Journal of allergy and clinical immunology</title><description><![CDATA[This multicenter, randomized, double-blind placebo-controlled study was conducted to assess the efficacy and safety of two doses of olopatadine nasal spray as a treatment for SAR (Mountain Cedar season). Patients assessed morning and evening reflective (refl) and instantaneous (inst) nasal and ocular symptoms including rhinorrhea, sneezing, itchy nose and congestion on a 0-3 scale. After a 3-21 day single blind placebo spray run-in period, 677 patients ages 12-81 with a minimum total nasal symptom score (TNSS) of 36 out of a possible 72 were randomized to olopatadine 0.4% (n=229), 0.6% (n=223), or placebo (n=225) 2 sprays/nostril BID for 2 weeks. Olopatadine HCl nasal spray 0.4% & 0.6% were significantly superior to placebo for percent change from baseline in overall refl (p=0.0002 & <0.0001, respectively) and inst (p=0.0015 & <0.0001, respectively) TNSS over a 2 week period. Olopatadine spray 0.6% was superior to placebo for individual nasal symptoms of runny nose, itchy nose, congestion and sneezing. The 0.4% spray was (generally) less effective than 0.6% but superior to placebo in most cases for the individual nasal symptoms. Treatment with Olopatadine HCl nasal spray 0.4% or 0.6%, BID, was safe and well tolerated. No serious adverse events related to any treatment were reported in this study. Olopatadine HCl nasal spray 0.4% & 0.6% are well tolerated and provide statistically significant improvements in symptoms in patients with seasonal allergic rhinitis.]]></description><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNotkEtLxDAUhYMoOD7-gKuAG120Jm2SJuBGBl-guHEfbpsbTanpmGQE_70dxtXlwDmHcz9CLjirOePqZqxHGELdMCZqxmuuxAFZcWa6SulGHpIVY4ZXqhPmmJzkPLJFt9qsSHqb5g0UcCEifVpPNEKGieZNgl8aMkXvcSjhBylERzN4pH5OtHwiLQmhfGEsdPY0I-Q5Lsmr13kbC4RI1-ggXVOYJkwfYaDpM8RQQj4jRx6mjOf_95S8P9y_r5-ql7fH5_XdS4Wa66rxAsBgL6XpezcY1bGByVa2vnFaKWjBNdgI5zrVN51z3vWdaY2UQgyq0217Si73tZs0f28xFzvO27RMzJZLJrTUQunFdbt34bLkJ2CyeQgYB3QhLY9bNwfLmd1BtqPdQbY7yJZxu0Bu_wBxF3JW</recordid><startdate>20040201</startdate><enddate>20040201</enddate><creator>Ratner, P.H.</creator><creator>Hampel, F.C.</creator><creator>Amar, N.J.</creator><creator>van Bavel, J.H.</creator><creator>Mohar, D.</creator><creator>Wall, G.M.</creator><creator>Brubaker, M.</creator><creator>Drake, M.</creator><creator>Potts, S.</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope></search><sort><creationdate>20040201</creationdate><title>Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (Mountain Cedar) allergic rhinitis</title><author>Ratner, P.H. ; Hampel, F.C. ; Amar, N.J. ; van Bavel, J.H. ; Mohar, D. ; Wall, G.M. ; Brubaker, M. ; Drake, M. ; Potts, S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-e818-2f4aa9eb559bbdc9670c05353f2d866a3ad2e24dd76b27ddfdb79395544c67833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Ratner, P.H.</creatorcontrib><creatorcontrib>Hampel, F.C.</creatorcontrib><creatorcontrib>Amar, N.J.</creatorcontrib><creatorcontrib>van Bavel, J.H.</creatorcontrib><creatorcontrib>Mohar, D.</creatorcontrib><creatorcontrib>Wall, G.M.</creatorcontrib><creatorcontrib>Brubaker, M.</creatorcontrib><creatorcontrib>Drake, M.</creatorcontrib><creatorcontrib>Potts, S.</creatorcontrib><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health &amp; Medical Complete (Alumni)</collection><collection>Nursing &amp; Allied Health Premium</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Ratner, P.H.</au><au>Hampel, F.C.</au><au>Amar, N.J.</au><au>van Bavel, J.H.</au><au>Mohar, D.</au><au>Wall, G.M.</au><au>Brubaker, M.</au><au>Drake, M.</au><au>Potts, S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (Mountain Cedar) allergic rhinitis</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><date>2004-02-01</date><risdate>2004</risdate><volume>113</volume><issue>2</issue><spage>S200</spage><epage>S201</epage><pages>S200-S201</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract><![CDATA[This multicenter, randomized, double-blind placebo-controlled study was conducted to assess the efficacy and safety of two doses of olopatadine nasal spray as a treatment for SAR (Mountain Cedar season). Patients assessed morning and evening reflective (refl) and instantaneous (inst) nasal and ocular symptoms including rhinorrhea, sneezing, itchy nose and congestion on a 0-3 scale. After a 3-21 day single blind placebo spray run-in period, 677 patients ages 12-81 with a minimum total nasal symptom score (TNSS) of 36 out of a possible 72 were randomized to olopatadine 0.4% (n=229), 0.6% (n=223), or placebo (n=225) 2 sprays/nostril BID for 2 weeks. Olopatadine HCl nasal spray 0.4% & 0.6% were significantly superior to placebo for percent change from baseline in overall refl (p=0.0002 & <0.0001, respectively) and inst (p=0.0015 & <0.0001, respectively) TNSS over a 2 week period. Olopatadine spray 0.6% was superior to placebo for individual nasal symptoms of runny nose, itchy nose, congestion and sneezing. The 0.4% spray was (generally) less effective than 0.6% but superior to placebo in most cases for the individual nasal symptoms. Treatment with Olopatadine HCl nasal spray 0.4% or 0.6%, BID, was safe and well tolerated. No serious adverse events related to any treatment were reported in this study. Olopatadine HCl nasal spray 0.4% & 0.6% are well tolerated and provide statistically significant improvements in symptoms in patients with seasonal allergic rhinitis.]]></abstract><cop>St. Louis</cop><pub>Mosby, Inc</pub><doi>10.1016/j.jaci.2004.01.164</doi></addata></record>
fulltext fulltext
identifier ISSN: 0091-6749
ispartof Journal of allergy and clinical immunology, 2004-02, Vol.113 (2), p.S200-S201
issn 0091-6749
1097-6825
language eng
recordid cdi_proquest_journals_1504858468
source ScienceDirect Freedom Collection
title Olopatadine HCl nasal spray is effective and safe for the treatment of seasonal (Mountain Cedar) allergic rhinitis
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A34%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_elsev&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Olopatadine%20HCl%20nasal%20spray%20is%20effective%20and%20safe%20for%20the%20treatment%20of%20seasonal%20(Mountain%20Cedar)%20allergic%20rhinitis&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Ratner,%20P.H.&rft.date=2004-02-01&rft.volume=113&rft.issue=2&rft.spage=S200&rft.epage=S201&rft.pages=S200-S201&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2004.01.164&rft_dat=%3Cproquest_elsev%3E3239719011%3C/proquest_elsev%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-e818-2f4aa9eb559bbdc9670c05353f2d866a3ad2e24dd76b27ddfdb79395544c67833%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=1504858468&rft_id=info:pmid/&rfr_iscdi=true